NCT02111187View on ClinicalTrials.gov

A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 18, 2017

Study Completion Date

January 18, 2017

Conditions
Prostate Cancer
Interventions
DRUG

LDE225

Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy

Trial Locations (1)

21205

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02111187 - A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer | Biotech Hunter | Biotech Hunter